The Manila Times

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-gra…

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...
Healthline

Non-small Cell Lung Cancer

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Seeking Alpha

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
Seeking Alpha

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value ...

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity ...
ascopubs.org

Locoregionally Advanced, BRAF V600L–Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of BRAF and MEK Inhibitors

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...
Ars Technica

Drug treatment of ameloblastoma associated with BRAF V600E mutation - datamining/contacts help requested

After significant prodding, I got my pathologist to screen for BRAF V600 mutation (not specifically V600E), and it is positive. So seems like targeted chemotherapy options would potentially be ...
Reuters

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...